拉米夫定治疗乙型肝炎的临床研究

Clinical study of lamivudine in the treatment of chronic hepatitis B

目的 :了解拉米夫定治疗慢性乙型肝炎的临床疗效。方法 :12 2例慢性乙型肝炎患者给予拉米夫定片剂 ,10 0mg·d-1,po ,疗程 1年。将血清HBVDNA ,HBeAg/抗HBe血清转换和ALT水平等作为评价抗病毒疗效的指标。结果 :12 2例患者中血清HBVDNA转阴 91例 ( 74 .6% ) ,HBeAg/抗HBe血清转换 2 4例 ( 19.7% ) ,ALT恢复正常 89例 ( 73 .0 % ) ;显效 2 2例 ( 18.0 % ) ,有效 64例 ( 5 2 .5 % ) ,总有效率 70 .5 %。未发现药物不良反应发生。结论 :拉米夫定可快速、高效抑制HBVDNA复制 ,使用方便、安全 ,是目前治疗慢性乙肝病毒感染的有效药物。

Objective:To evaluate the clinical efficacy of lam ivudine in the treatment of chronic hepatitis B.Methods:122 patients with chronic hepatitis B received 100mg lamivudin e orally daily for one year.HBVDNA,ALT and HBeAg seroconversion in serum were ex amined before,during and after the treatment.Results:91 patients(74.6%) were conversed to HBVDNA negative.The rate of HBeAg seroconversion was 19.7%.ALT values of 89 patients(73.0%) were normal. 122 patients with chronic hepatitis B with an effective rate of 70.5% were found .Conclusion:Lamivudine resulted in the clearance of HBVDNA and prompted HBeAg seroconversion of the patients with chronic hepatitis B.It appeared to be a useful drug in the treatment of chronic hepatitis B.